About Endocyte (NASDAQ:ECYT)
Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ECYT
CUSIP29269A10
Phone765-463-7175
Debt
Debt-to-Equity RatioN/A
Current Ratio21.71%
Quick Ratio21.71%
Price-To-Earnings
Trailing P/E Ratio-8.79
Forward P/E Ratio-11.91
P/E GrowthN/A
Sales & Book Value
Annual Sales$70,000.00
Price / Sales8,916.84
Cash FlowN/A
Price / CashN/A
Book Value$1.99 per share
Price / Book4.55
Profitability
EPS (Most Recent Fiscal Year)($1.00)
Net Income$-55,060,000.00
Net Margins-78,662.86%
Return on Equity-40.33%
Return on Assets-38.40%
Miscellaneous
Employees44
Outstanding Shares68,970,000
Endocyte (NASDAQ:ECYT) Frequently Asked Questions
What is Endocyte's stock symbol?
Endocyte trades on the NASDAQ under the ticker symbol "ECYT."
How were Endocyte's earnings last quarter?
Endocyte (NASDAQ:ECYT) announced its quarterly earnings data on Monday, February, 26th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.02. The biopharmaceutical company earned $0.01 million during the quarter. Endocyte had a negative net margin of 78,662.86% and a negative return on equity of 40.33%. The firm's revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.26) EPS. View Endocyte's Earnings History.
When is Endocyte's next earnings date?
What price target have analysts set for ECYT?
4 analysts have issued 12-month target prices for Endocyte's stock. Their forecasts range from $7.00 to $7.00. On average, they expect Endocyte's stock price to reach $7.00 in the next twelve months. View Analyst Ratings for Endocyte.
Are investors shorting Endocyte?
Endocyte saw a increase in short interest in the month of March. As of March 15th, there was short interest totalling 4,397,809 shares, an increase of 131.5% from the February 28th total of 1,899,651 shares. Based on an average daily trading volume, of 6,654,429 shares, the short-interest ratio is currently 0.7 days. Currently, 14.6% of the shares of the stock are short sold.
Who are some of Endocyte's key competitors?
Some companies that are related to Endocyte include Acadia Pharmaceuticals (ACAD), Supernus Pharmaceuticals (SUPN), Puma Biotechnology (PBYI), Horizon Pharma (HZNP), Portola Pharmaceuticals (PTLA), Global Blood Therapeutics (GBT), AnaptysBio (ANAB), Heron Therapeutics (HRTX), Motif (MTFB), Medicines (MDCO), Corcept Therapeutics (CORT), Insmed (INSM), Intercept Pharmaceuticals (ICPT), Esperion Therapeutics (ESPR) and Spectrum Pharmaceuticals (SPPI).
Who are Endocyte's key executives?
Endocyte's management team includes the folowing people:
- Mr. Michael A. Sherman, CEO, Pres & Director (Age 52)
- Dr. Philip S. Low, Co-Founder, Chief Science Officer & Director (Age 70)
- Ms. Katherine K. Parker, VP of HR (Age 53)
- Dr. Alison A. Armour, Chief Medical Officer (Age 54)
- Dr. Christopher P. Leamon Ph.D., VP of R&D (Age 52)
Has Endocyte been receiving favorable news coverage?
News coverage about ECYT stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Endocyte earned a daily sentiment score of 0.18 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 46.30 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
How do I buy shares of Endocyte?
Shares of ECYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Endocyte's stock price today?
One share of ECYT stock can currently be purchased for approximately $9.19.
How big of a company is Endocyte?
Endocyte has a market capitalization of $631.76 million and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-55,060,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Endocyte employs 44 workers across the globe.
How can I contact Endocyte?
Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company can be reached via phone at 765-463-7175.
MarketBeat Community Rating for Endocyte (ECYT)
MarketBeat's community ratings are surveys of what our community members think about Endocyte and other stocks. Vote "Outperform" if you believe ECYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ECYT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Endocyte (NASDAQ:ECYT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Endocyte in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible downside of 22.65%. The high price target for ECYT is $7.00 and the low price target for ECYT is $7.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 2.50 | 2.67 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $7.00 | $7.00 | $7.00 | $7.00 |
| Price Target Upside: | 22.65% downside | 13.15% downside | 92.84% upside | 92.84% upside |
Endocyte (NASDAQ:ECYT) Consensus Price Target History
Endocyte (NASDAQ:ECYT) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Endocyte (NASDAQ:ECYT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Endocyte (NASDAQ ECYT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.65%
Institutional Ownership Percentage: 29.14%
Endocyte (NASDAQ ECYT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/9/2018 | Christopher P Leamon | VP | Sell | 5,036 | $9.07 | $45,676.52 | 143,470 |  |
| 12/28/2017 | Philip S Low | Insider | Sell | 50,511 | $4.41 | $222,753.51 | | |
| 12/28/2017 | Philip S Low | Insider | Sell | 50,511 | $4.41 | $222,753.51 | 354,050 | |
| 12/1/2017 | Christopher P Leamon | VP | Sell | 23,231 | $5.04 | $117,084.24 | 150,579 | |
| 11/13/2017 | Philip S Low | Insider | Buy | 5,600 | $4.84 | $27,104.00 | 283,005 | |
| 12/30/2016 | Christopher P. Leamon | VP | Sell | 23,244 | $2.55 | $59,272.20 | | |
| 5/10/2016 | Philip S Low | Insider | Buy | 11,375 | $3.52 | $40,040.00 | 206,606 | |
| 1/19/2016 | Fred A. Middleton | Director | Buy | 10,000 | $2.79 | $27,900.00 | 200,999 | |
| 1/15/2016 | Fred A. Middleton | Director | Buy | 20,000 | $2.80 | $56,000.00 | 200,999 | |
| 4/9/2014 | Allen Ritter | VP | Sell | 1,000 | $21.16 | $21,160.00 | 34,282 | |
| 3/21/2014 | Allen Ritter | VP | Sell | 8,000 | $33.11 | $264,880.00 | 12,722 | |
| 2/14/2014 | Philip Low | Insider | Sell | 6,000 | $15.00 | $90,000.00 | 200,819 | |
| 12/2/2013 | P Ron Ellis | CEO | Sell | 3,000 | $12.00 | $36,000.00 | 29,154 | |
| 9/16/2013 | Allen Ritter | VP | Sell | 2,000 | $17.06 | $34,120.00 | 15,722 | |
| 9/12/2013 | David Meek | Insider | Sell | 10,000 | $15.50 | $155,000.00 | | |
| 9/3/2013 | P Ron Ellis | CEO | Sell | 3,000 | $14.54 | $43,620.00 | 29,154 | |
| 8/30/2013 | Allen Ritter | VP | Sell | 6,000 | $14.36 | $86,160.00 | 17,722 | |
| 8/6/2013 | Chandra Lovejoy | VP | Sell | 7,000 | $17.29 | $121,030.00 | | |
| 8/1/2013 | P Ron Ellis | CEO | Sell | 3,000 | $18.12 | $54,360.00 | 29,154 | |
| 7/15/2013 | P Ron Ellis | CEO | Sell | 3,000 | $17.01 | $51,030.00 | | |
| 5/28/2013 | Ann Hanham | Director | Sell | 9,900 | $14.10 | $139,590.00 | | |
| 5/22/2013 | Ann Hanham | Director | Sell | 40,000 | $14.38 | $575,200.00 | | |
| 5/17/2013 | Ann Hanham | Director | Sell | 37,200 | $14.41 | $536,052.00 | | |
| 5/17/2013 | Binh Nguyen | VP | Sell | 17,300 | $14.42 | $249,466.00 | | |
| 5/15/2013 | Ann Hanham | Director | Sell | 40,200 | $14.69 | $590,538.00 | | |
| 5/14/2013 | Christopher P Leamon | VP | Sell | 5,000 | $14.70 | $73,500.00 | | |
| 2/25/2013 | Chandra D Lovejoy | VP | Sell | 2,102 | $9.70 | $20,389.40 | | |
| 12/26/2012 | Chandra D Lovejoy | VP | Sell | 2,209 | $9.05 | $19,991.45 | | |
| 11/26/2012 | Chandra D Lovejoy | VP | Sell | 2,209 | $8.72 | $19,262.48 | | |
(Data available from 1/1/2013 forward)
Endocyte (NASDAQ ECYT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Endocyte (ECYT) Expected to Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - April 18 at 9:31 AM |
| Wedbush Equities Analysts Boost Earnings Estimates for Endocyte (ECYT)
www.americanbankingnews.com - April 18 at 7:58 AM |
 | BRIEF-Endocyte Says Data Presented At AACR Show That EC17 Penetrates Solid Tumors Within Minutes And Is ...
www.reuters.com - April 16 at 9:56 AM |
 | Endocyte Presents Data from its CAR T Platform at American Association for Cancer Research (AACR) Annual Meeting ...
globenewswire.com - April 16 at 9:56 AM |
 | Endocyte Presents Data from its CAR T Platform at American Association for Cancer Research (AACR) Annual Meeting 2018
finance.yahoo.com - April 16 at 9:56 AM |
| Endocyte (ECYT) Earns Buy Rating from Analysts at Jefferies Group
www.americanbankingnews.com - April 13 at 10:37 AM |
 | Endocyte Inc. (ECYT) Is Approaching The Highs Of The Year
www.nasdaq.com - April 13 at 10:16 AM |
| Endocyte (ECYT) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - April 8 at 12:54 PM |
| Endocyte (ECYT) Receives "Hold" Rating from Cowen
www.americanbankingnews.com - April 8 at 10:49 AM |
| New Analyst Coverage Puts Spotlight on 5 Stocks
finance.yahoo.com - April 4 at 5:24 PM |
| Endocyte (ECYT) Upgraded to "Buy" at ValuEngine
www.americanbankingnews.com - April 3 at 4:48 PM |
| Endocyte, Inc. (ECYT) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 3 at 3:08 AM |
| Brokerages Expect Endocyte, Inc. (ECYT) Will Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - April 1 at 7:23 AM |
| Endocyte (ECYT) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - March 31 at 6:04 PM |
| Endocyte, Inc. (ECYT) Short Interest Up 131.5% in March
www.americanbankingnews.com - March 28 at 2:44 AM |
| Endocyte (ECYT) Upgraded by Cowen to "Outperform"
www.americanbankingnews.com - March 24 at 10:39 PM |
| Head to Head Survey: Mateon Therapeutics (MATN) vs. Endocyte (ECYT)
www.americanbankingnews.com - March 21 at 11:25 AM |
| Endocyte (ECYT) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 18 at 6:40 PM |
| BRIEF-Endocyte Nominates Dawn Svoronos For Election To Its Board
www.reuters.com - March 16 at 10:58 AM |
| Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2018
finance.yahoo.com - March 15 at 4:09 PM |
| Brokerages Expect Endocyte, Inc. (ECYT) to Post -$0.18 Earnings Per Share
www.americanbankingnews.com - March 15 at 5:18 AM |
| Insider Selling: Endocyte, Inc. (ECYT) VP Sells 5,036 Shares of Stock
www.americanbankingnews.com - March 12 at 4:46 PM |
| Endocyte (ECYT) Now Covered by Wells Fargo & Co
www.americanbankingnews.com - March 10 at 12:00 AM |
| Endocyte, Inc. (ECYT) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 9 at 4:52 PM |
| Why Endocyte Stock Is on the Move Today
finance.yahoo.com - March 8 at 4:11 PM |
 | Endocyte's Lu-PSMA-617: Will It Be Lucky This Time - Seeking Alpha
seekingalpha.com - March 5 at 4:18 PM |
| Endocyte (ECYT) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - March 3 at 12:00 PM |
| Endocyte Announces Closing of Public Offering of Common Stock
finance.yahoo.com - March 3 at 10:36 AM |
| Investors Buy High Volume of Endocyte Call Options (ECYT)
www.americanbankingnews.com - March 2 at 7:32 AM |
| Endocyte Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - March 1 at 4:04 PM |
| Endocyte up another 7% as Cowen upgrades - Seeking Alpha
seekingalpha.com - March 1 at 4:04 PM |
| Endocyte Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - March 1 at 4:04 PM |
| Endocyte, Inc. (ECYT) to Post Q1 2018 Earnings of ($0.20) Per Share, Wedbush Forecasts
www.americanbankingnews.com - March 1 at 8:36 AM |
| Endocyte (ECYT) Raised to Hold at ValuEngine
www.americanbankingnews.com - February 28 at 10:48 PM |
| Endocyte, Inc. Expected to Earn FY2022 Earnings of ($0.06) Per Share (ECYT)
www.americanbankingnews.com - February 28 at 4:51 PM |
| Endocyte prices stock offering at $4.20; shares up 30%
seekingalpha.com - February 28 at 11:29 AM |
| Endocyte Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - February 28 at 10:30 AM |
| Endocyte Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 28 at 10:30 AM |
 | Endocyte (ECYT) Reports Supply Agreement with ITM for EndolucinBeta in Phase 3 VISION Trial
www.streetinsider.com - February 27 at 10:44 AM |
| Endocyte (ECYT) Reports Wider-Than-Estimated Loss in Q4
finance.yahoo.com - February 27 at 10:44 AM |
| Endocyte (ECYT) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - February 26 at 11:18 AM |
 | Endocyte (ECYT) Posts Wider than Expected Loss in Q4
www.zacks.com - February 26 at 10:11 AM |
| Endocyte and ITM Announce Supply Agreement for No-Carrier-Added Lutetium for the Phase 3 VISION Trial
finance.yahoo.com - February 26 at 10:11 AM |
| Endocyte Announces Phase 3 VISION Trial and Provides Update on Corporate Strategy and Reports Fourth Quarter and Year End 2017 Financial Results
finance.yahoo.com - February 26 at 10:11 AM |
| Endocyte net loss improves in Q4
seekingalpha.com - February 26 at 8:26 AM |
| Endocyte, Inc. (ECYT) Expected to Announce Earnings of -$0.16 Per Share
www.americanbankingnews.com - February 26 at 5:14 AM |
| Endocyte Announces Fourth Quarter and Full Year 2017 Earnings Conference Call
finance.yahoo.com - February 23 at 10:20 AM |
| Zacks Investment Research Lowers Endocyte (ECYT) to Sell
www.americanbankingnews.com - February 15 at 2:48 PM |
| Endocyte (ECYT) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 9 at 10:12 AM |
| Endocyte (ECYT) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - February 1 at 11:35 AM |
Endocyte (NASDAQ:ECYT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Endocyte (NASDAQ:ECYT) Income Statement, Balance Sheet and Cash Flow Statement
Endocyte (NASDAQ ECYT) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
